Gemcis
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk (NCT05672537) | Tianjin Medical University Cancer Institute and Hospital | 2023-01-20 |
Track Gemcis automatically
Every clearance here is in the API, with alerts when new ones post.